Menu
Menu
Achieve scalable analysis of solid tumors with an agile and modular approach to comprehensive genomic profiling (CGP), eliminating the need for multiple tests.
Built on the expert-designed content of MSK-IMPACT® and combined with the adaptive analytics of the SOPHiA DDM™ Platform, MSK-IMPACT® Flex powered with SOPHiA DDM™ delivers high-resolution profiling of complex biomarkers from DNA and RNA in a single, end-to-end workflow.
Built on the backbone of MSK-IMPACT®, curated by Memorial Sloan Kettering Cancer Center (MSK) experts and verified in over 1,000 MSK publications.
Detect all major variant classes (SNVs/Indels, CNVs, partner-agnostic fusions, exon-skipping events, gene expression) and complex signatures (TMB, MSI, HRD).
Add RNA and HRD analysis at the sample level to tailor biomarker coverage for each case, optimizing cost efficiency.
Boost lab efficiency with a single, streamlined, end-to-end NGS workflow that allows you to analyze multiple data modalities in one sequencing run. All variant detection and interpretation steps are powered by the SOPHiA DDM™ Platform, giving you full control over your data and samples.
The modular architecture of the SOPHiA DDM™ Platform enables a truly flexible approach to CGP. You can easily integrate analytical modules – RNA analysis and/or low-pass whole genome sequencing–based HRD detection – at the sample level to meet the specific needs of your institution and deliver the most relevant insights for every case.
Take your research further by complementing your tissue analysis with SOPHiA DDM™ for Liquid Biopsy, enabling advanced monitoring of resistance and a comprehensive view of the tumor landscape.
| No. of genes |
• 533 DNA genes (including 505 from MSK-IMPACT®) • 140 RNA genes |
|
|---|---|---|
| Disease covered | Multi-cancer (any solid tumor) | |
| Sample type | FFPE, fresh frozen | |
| Recommended input amount |
• 50 ng DNA • 50 ng RNA |
|
| Sequencer compatibility |
• Illumina® NextSeq® 550/1000/2000 • Illumina® NovaSeq™ 6000, X • Compatible with MGI and Element sequencers – SOPHiA DDM™ MaxCare Program is recommended to verify performance |
|
| Detected variants & biomarkers |
From DNA
• SNVs/Indels in 533 genes • Whole gene amplifications and deletions in 520 genes • Gene-level and exon-level CNVs in 49 genes • TERT promoter • TMB • MSI • HRD (optional) |
From RNA (optional) • Partner-agnostic fusions in 135 genes • Exon skipping events in 9 genes • Gene expression in 56 genes |
| Limit of detection at 95% (LOD95) | 5% | |
| Recommended paired-end reads |
• DNA capture – 51 million • RNA capture – 11 million • DNA whole genome sequencing (at ~1x coverage) – 20 million |
|
| Library preparation time |
• 1.5 days (DNA only) • 2.5 days (DNA+RNA) |
|
| Analysis time* |
DNA only – <10 hours DNA + RNA – <15 hours |
|
*Analysis time dependent on multiplexing and server load.
| SOPHiA DDM™ HCS v1.1 (RUO) | SOPHiA DDM™ HCS v2.0 (RUO) | SOPHiA DDM™ Dx HCS (CE-IVD) | |
|---|---|---|---|
| Diseases covered | Hereditary Breast and Ovarian Cancer (HBOC), Lynch and various intestinal polyposis syndromes | Breast, ovarian, prostate, abdominal, endocrine & neuroendocrine, nervous system, renal, and skin | Breast and ovarian cancers and colorectal syndromes |
| Diseases covered | 26 + PMS2CL | 82 + PMS2CL | 26 + PMS2CL |
| Target region size | 105 kb | 285 kb | 105 kb |
| Sample type | Blood | Blood | Blood |
| DNA input amount | 200 ng | 50 ng | 200 ng |
| Sequence |
|
|
|
| Library prep time | 1.5 days | 1.5 days | 2 days |
| Analysis time from FASTQ | 4 hours | 4 hours | < 6 hours |
| Detected variants |
|
|
|
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
